Some years ago, a patient came to see me who had recently survived a heart attack. He was 53 years old. Non-smoker. Healthy weight. Exercised regularly. His LDL — the cholesterol level most doctors treat as the primary cardiovascular indicator — was 72 mg/dL. His primary care physician had noted that his lipids looked fine and couldn't really explain his heart attack. Nobody, in years of routine check-ups, had found anything to worry about.
We ordered a full panel. When his Lp(a) came back at 178 nmol/L — well into the 95th percentile — the mystery was solved. He had been carrying a significant, heritable cardiovascular risk for decades. Nobody had looked for it. And because nobody had looked for it, nobody had done anything about it.
Even in 2026, that scenario is more common than it should be. Lipoprotein(a) — abbreviated Lp(a), pronounced "L-P-little-a" — is one of the most well-studied cardiovascular risk factors we have. The evidence linking elevated Lp(a) to heart attack and stroke is large, robust, and causal. Yet it remains absent from most standard lipid panels, routine check-ups, and doctors' working vocabulary outside specialist cardiology.
Elevated Lp(a) affects approximately one in five people globally — and the vast majority of them have never been told.
A particle with three distinct weapons
To understand why Lp(a) matters, it helps to understand what it actually is — and why it is not simply another form of LDL cholesterol.
Lp(a) is a lipoprotein particle circulating in the bloodstream with the same lipid-carrying core as LDL. But it has one critical structural difference: an additional protein called apolipoprotein(a), attached to its surface. That structural addition gives Lp(a) three distinct mechanisms of harm that LDL alone does not share.[5]
First, like LDL, Lp(a) is atherogenic — it deposits in artery walls, contributes to plaque formation, and drives the progressive narrowing of coronary vessels that precedes most heart attacks.
Second, and more distinctively, Lp(a) is prothrombotic. Apolipoprotein(a) has a structural resemblance to plasminogen — the protein responsible for dissolving blood clots. Lp(a) competes with plasminogen for binding sites, interfering with the body's natural clot-clearing mechanism. At elevated concentrations, this increases the risk of blood clots and thrombotic events: not just slow arterial narrowing, but acute clot formation.[5]
Third, Lp(a) particles carry oxidized lipids on their surface. These lipids trigger inflammation in the blood vessels and promote the progression of both coronary artery disease and calcific aortic valve stenosis.[4]
It is this combination — atherogenic, prothrombotic, and pro-inflammatory, operating simultaneously — that makes elevated Lp(a) a qualitatively different risk than elevated LDL. It explains why a patient can have perfectly managed LDL cholesterol and still face a meaningfully elevated risk of a cardiovascular event.
Why your lifestyle cannot fix it — and why that changes everything
The single most important thing to understand about Lp(a) is that it is almost entirely determined by genetics. Specifically, by inherited variants in the LPA gene, which governs the size and production rate of apolipoprotein(a). Approximately 90% of the variation in Lp(a) levels between people is heritable — making it one of the most genetically determined cardiovascular risk factors known.[3]
This matters for two reasons, and they pull in opposite directions.
On one hand, it means that knowing your Lp(a) is genuinely informative. Unlike LDL — which fluctuates with diet, weight, and medications — your Lp(a) is essentially stable across your adult life. A single measurement, at any age, gives you a reliable picture of a lifelong risk profile. You only need to test once.
On the other hand, it means that the standard advice given to cardiovascular risk patients — exercise more, eat less saturated fat, lose weight, take a statin — while important, does not address elevated Lp(a). Statins do not lower Lp(a); in some patients, they raise it modestly.[3] A patient who follows every piece of guideline-concordant lifestyle advice can still carry an unmanaged, elevated Lp(a) risk year after year. Doing everything right is not enough, if the right things have no effect on this particular risk factor.
The blind spot in standard cardiovascular risk scoring
The two most widely used cardiovascular risk calculators in clinical practice — the Framingham Risk Score — do not include Lp(a). Neither does the European SCORE system in its standard form. Even the PREVENT™ (Predicting Risk of Cardiovascular Disease EVENTs) equations, the recently recommended score developed by the American Heart Association, do not directly include Lp(a) as a variable in their core calculation. This creates a systematic blind spot: a patient with elevated Lp(a) and otherwise unremarkable lipids will be categorised as low or intermediate risk by every standard tool, while their actual cardiovascular risk is substantially higher.
The evidence documenting this gap is substantial. A landmark meta-analysis by the Emerging Risk Factors Collaboration, analysing data from 36 prospective studies and more than 126,000 participants, found that elevated Lp(a) was independently associated with increased risk of coronary heart disease and stroke, even after adjusting for LDL, HDL, triglycerides, and all other standard risk factors.[2] The relationship held at all levels of LDL — meaning there is no LDL threshold below which high Lp(a) becomes clinically irrelevant.
Critically, a Mendelian randomization study — a research method that uses genetic variants as natural experiments to determine if a specific risk factor actually causes a disease — published in JAMA established the relationship as causal, not merely associative. Individuals who inherited genetic variants that raise Lp(a) had a corresponding increase in myocardial infarction risk, confirming that Lp(a) itself drives cardiovascular disease and is not simply a bystander marker.[1]
Guideline bodies have historically been slow to respond; the 2018 ACC/AHA cholesterol guidelines moved Lp(a) into the "risk-enhancing factors" category for borderline treatment decisions but stopped short of universal screening.[6] While the 2019 ESC/EAS guidelines were earlier to recommend a one-time lifetime measurement for all adults,[7] the 2026 ACC/AHA Guideline on the Management of Dyslipidemia formalises this shift by officially recommending that all adults have their Lp(a) concentration measured at least once. This update elevates universal testing to a Class 1 recommendation, aiming to ensure that high heritable risk is identified early and clinical practice finally aligns with the evidence of Lp(a) as an independent cardiovascular driver. Most physicians have not yet translated that recommendation into practice.
What changes when you know your number?
The clinical value of Lp(a) measurement is not academic. It directly changes the decisions a physician will make. An Lp(a) level of 125 nmol/L (50 mg/dL) or higher is considered a risk-enhancing factor that should prompt earlier and more intensive management of other modifiable risk factors like LDL-C and blood pressure. For patients with elevated Lp(a), the following interventions all shift in their clinical calculus:
The drugs being developed specifically to target Lp(a)
For most of Lp(a)'s clinical history, there was a frustrating asymmetry: strong evidence that elevated Lp(a) was harmful, but no therapeutic tools to address it directly. That is now changing, with four classes of Lp(a)-specific drugs in late-stage development — all achieving reductions in Lp(a) that were unimaginable even five years ago.
| Drug | Mechanism | Lp(a) reduction | Phase / Trial |
|---|---|---|---|
| Pelacarsen Antisense oligonucleotide |
Targets LPA gene mRNA in hepatocytes; reduces Lp(a) production at source | ~80% | Phase 3 HORIZON trial — cardiovascular outcomes primary endpoint[10] |
| Olpasiran Small interfering RNA (siRNA) |
RNA silencing of LPA gene; quarterly or twice-yearly dosing | ≥90% | Phase 2 OCEAN(a) — NEJM 2022 — outcomes trial underway[11] |
| Muvalaplin Oral small molecule |
Disrupts apo(a)–apoB bond; prevents Lp(a) particle assembly; first oral agent | ~65–80% | Phase 2 results — JAMA 2023[12] |
| Lepodisiran Long-duration siRNA (Eli Lilly) |
GalNAc-conjugated siRNA silencing hepatic LPA mRNA; single injection active for up to 12 months | ~94% | Phase 2 — NEJM 2025 — Phase 3 ACCLAIM-Lp(a) underway[13] |
The clinical significance of this pipeline cannot be overstated. If any of these agents demonstrates a cardiovascular outcomes benefit in Phase 3 trials — which is the central clinical question all four programmes are designed to answer — Lp(a) will immediately become one of the most actionable biomarkers in preventive cardiology.[10][11][13]
Not knowing your Lp(a) doesn't make the risk disappear. It makes you unaware of it — and unpositioned to act when the first targeted therapies are approved.
This creates a specific and time-sensitive argument for testing now. A patient who does not know their Lp(a) today will not be in a position to access targeted Lp(a) therapy the moment those drugs are approved — because their physician will have no indication to prescribe it. The window between now and approval is the right moment to identify which patients are candidates. There are also ongoing opportunities to enrol in clinical trials targeting Lp(a) and cardiovascular outcomes.
Who should be tested, and when
The short answer, per the current European Atherosclerosis Society consensus and the 2026 ACC/AHA Guideline on the Management of Dyslipidemia, is: everyone, once. Because Lp(a) is genetically determined and stable across adult life, a single measurement at any age gives reliable, lifelong information about this component of cardiovascular risk. There is no clinical justification for not knowing a number that is this informative, and this rarely changes. Yet, certain groups have the most to gain from testing promptly:
- Family history of early cardiovascular disease — a parent or sibling with a heart attack or stroke before age 60 raises the probability of elevated Lp(a) significantly, given its heritability.
- Premature cardiovascular events without a clear explanation — any patient who has had a myocardial infarction, stroke, or other atherosclerotic event with seemingly well-managed LDL should have Lp(a) measured.
- Intermediate cardiovascular risk by standard scoring — this is exactly the group in which elevated Lp(a) is most likely to reclassify risk upward, and therefore most likely to change the treatment decision.
- Calcific aortic valve stenosis — given the causal evidence linking Lp(a) to valve disease, anyone with early aortic valve calcification should know their Lp(a) status.
The test itself is a single blood draw. It is not expensive. The result is stable — you need not repeat it. The clinical return on a single Lp(a) measurement, in the right patient, is potentially a heart attack that doesn't happen.
The marker standard care continues to overlook
Lp(a) is not a niche marker or an emerging theory. The evidence supporting its role in cardiovascular disease is decades old, robust, and causal. Guidelines from both the European and American cardiology communities have recommended its measurement. A wave of powerful new therapies targeting it specifically are in late-stage trials.
And yet the majority of people who carry an elevated Lp(a) — roughly one in five of the global population — have never been told. Their doctors have never ordered the test. It is not on the standard panel. It is not in the workflow. It falls into one of the cleanest examples in medicine of a known, measurable, clinically meaningful risk factor that the structure of routine care continues to miss.
Preventive medicine, at its most fundamental level, is about finding what standard care doesn't look for, before it becomes a problem you have to manage instead. Lp(a) is a biomarker in cardiovascular disease for approximately 1.4 billion people in the world today. Most of them don't know it.
Your Lp(a) is one test away.
Breeoot measures Lp(a) as part of every member's initial biomarker panel — and interprets it in the full clinical context of your cardiovascular risk profile. Schedule a consultation to understand what your numbers mean.
Schedule a consultation →- Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331–2339.
- Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412–423.
- Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853.
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–3946.
- Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188.
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
- Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107.
- Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244–255.
- O'Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a). N Engl J Med. 2022;387(20):1855–1864.
- Nicholls SJ, Nissen SE, Bhatt DL, et al. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation. JAMA. 2023;330(11):1042–1053.
- Nissen SE, Wolski K, Scrimgeour AC, et al. Lepodisiran — a long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med. 2025;392(17):1673–1684.